Literature DB >> 29290933

Prognostic impact of Ikaros expression in lenalidomide-treated multiple myeloma.

Jan Krönke1, Stefan Knop1, Christian Langer1.   

Abstract

Entities:  

Keywords:  gene expression; ikaros; lenalidomide; multiple myeloma; prognostic marker

Year:  2017        PMID： 29290933      PMCID： PMC5739718          DOI： 10.18632/oncotarget.22572

Source DB:  PubMed          Journal:  Oncotarget        ISSN： 1949-2553


× No keyword cloud information.
  8 in total

1.  Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.

Authors:  Yuan Xiao Zhu; Esteban Braggio; Chang-Xin Shi; K Martin Kortuem; Laura A Bruins; Jessica E Schmidt; Xiu-Bao Chang; Paul Langlais; Moulun Luo; Patrick Jedlowski; Betsy LaPlant; Kristina Laumann; Rafael Fonseca; P Leif Bergsagel; Joseph Mikhael; Martha Lacy; Mia D Champion; A Keith Stewart
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

2.  IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).

Authors:  J Krönke; F Kuchenbauer; M Kull; V Teleanu; L Bullinger; D Bunjes; A Greiner; S Kolmus; S Köpff; M Schreder; L-O Mügge; C Straka; M Engelhardt; H Döhner; H Einsele; F Bassermann; R Bargou; S Knop; C Langer
Journal:  Leukemia       Date:  2016-12-26       Impact factor: 11.528

3.  Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.

Authors:  Kartik Sehgal; Rituparna Das; Lin Zhang; Rakesh Verma; Yanhong Deng; Mehmet Kocoglu; Juan Vasquez; Srinivas Koduru; Yan Ren; Maria Wang; Suzana Couto; Mike Breider; Donna Hansel; Stuart Seropian; Dennis Cooper; Anjan Thakurta; Xiaopan Yao; Kavita M Dhodapkar; Madhav V Dhodapkar
Journal:  Blood       Date:  2015-04-13       Impact factor: 22.113

4.  IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma.

Authors:  Arnold Bolomsky; Wolfgang Hübl; Stefano Spada; Ercan Müldür; Karin Schlangen; Daniel Heintel; Alberto Rocci; Adalbert Weißmann; Veronique Fritz; Martin Willheim; Niklas Zojer; Antonio Palumbo; Heinz Ludwig
Journal:  Am J Hematol       Date:  2017-02-01       Impact factor: 10.047

5.  Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.

Authors:  Jan Krönke; Namrata D Udeshi; Anupama Narla; Peter Grauman; Slater N Hurst; Marie McConkey; Tanya Svinkina; Dirk Heckl; Eamon Comer; Xiaoyu Li; Christie Ciarlo; Emily Hartman; Nikhil Munshi; Monica Schenone; Stuart L Schreiber; Steven A Carr; Benjamin L Ebert
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728

6.  Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.

Authors:  Ruth Eichner; Michael Heider; Vanesa Fernández-Sáiz; Frauke van Bebber; Anne-Kathrin Garz; Simone Lemeer; Martina Rudelius; Bianca-Sabrina Targosz; Laura Jacobs; Anna-Maria Knorn; Jolanta Slawska; Uwe Platzbecker; Ulrich Germing; Christian Langer; Stefan Knop; Herrmann Einsele; Christian Peschel; Christian Haass; Ulrich Keller; Bettina Schmid; Katharina S Götze; Bernhard Kuster; Florian Bassermann
Journal:  Nat Med       Date:  2016-06-13       Impact factor: 53.440

7.  High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide.

Authors:  Maryam Pourabdollah; Mohammad Bahmanyar; Eshetu G Atenafu; Donna Reece; Jian Hou; Hong Chang
Journal:  J Hematol Oncol       Date:  2016-11-21       Impact factor: 17.388

8.  The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.

Authors:  Gang Lu; Richard E Middleton; Huahang Sun; MarkVic Naniong; Christopher J Ott; Constantine S Mitsiades; Kwok-Kin Wong; James E Bradner; William G Kaelin
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728
  8 in total
  2 in total

1.  RNA sequencing identifies novel regulated IRE1-dependent decay targets that affect multiple myeloma survival and proliferation.

Authors:  Ana B Herrero; Norma C Gutiérrez; Dalia Quwaider; Luis A Corchete; Marta Martín-Izquierdo; Jesús M Hernández-Sánchez; Elizabeta A Rojas; Ignacio J Cardona-Benavides; Ramón García-Sanz
Journal:  Exp Hematol Oncol       Date:  2022-03-31

2.  Pathogenic germline IKZF1 variant alters hematopoietic gene expression profiles.

Authors:  Seth A Brodie; Payal P Khincha; Neelam Giri; Aaron J Bouk; Mia Steinberg; Jieqiong Dai; Lea Jessop; Frank X Donovan; Settara C Chandrasekharappa; Kelvin C de Andrade; Irina Maric; Steven R Ellis; Lisa Mirabello; Blanche P Alter; Sharon A Savage
Journal:  Cold Spring Harb Mol Case Stud       Date:  2021-08-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.